Document Detail


Impact of data from recent clinical trials on strategies for treating patients with type 2 diabetes mellitus.
MedLine Citation:
PMID:  20191079     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Type 2 diabetes is associated with increased risk for the development of cardiovascular disease (CVD) secondary to hyperglycemia's toxicity to blood vessels. The escalating incidence of CVD among patients with type 2 diabetes has prompted research into how lowering glycated hemoglobin (HbA(1c)) may improve CVD-related morbidity and mortality. Data from recent studies have shown that some patients with type 2 diabetes actually have increased mortality after achieving the lowest possible HbA(1c) using intensive antidiabetes treatment. Multiple factors, such as baseline HbA(1c), duration of diabetes, pancreatic beta-cell decline, presence of overweight/obesity, and the pharmacologic durability of antidiabetes medications influence diabetes treatment plans and therapeutic results. Hypertension and dyslipidemia are common comorbidities in patients with type 2 diabetes, which impact the risk of CVD independently of glycemic control. Consideration of all of these risk factors provides the best option for reducing morbidity and mortality in patients with type 2 diabetes. Based on the results of recent trials, the appropriate use of current antidiabetes therapies can optimize glycemic control, but use of intensive glucose-lowering therapy will need to be tailored to individual patient needs and risks.
Authors:
Pasquale J Palumbo; Jonathan M Wert
Related Documents :
15574199 - Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates...
14668699 - The relation of insulin resistance syndromes to risk of cardiovascular disease.
15063599 - Diabetes care and complications in a remote primary health care setting.
10754469 - Defective nitric oxide synthesis: a link between metabolic insulin resistance, sympathe...
15051749 - Preventing type ii diabetes mellitus.
19427049 - Cigarette smoking, smoking cessation, and diabetes.
15778929 - Nutrient-stimulated glp-1 release in normal-weight men and women.
17964829 - The activity of calpains in lymphocytes is glucose-dependent and is decreased in diabet...
2849069 - Decreased central gaba b receptor binding sites in diabetic rats.
Publication Detail:
Type:  Journal Article; Review     Date:  2010-02-04
Journal Detail:
Title:  Vascular health and risk management     Volume:  6     ISSN:  1178-2048     ISO Abbreviation:  Vasc Health Risk Manag     Publication Date:  2010  
Date Detail:
Created Date:  2010-03-01     Completed Date:  2011-01-27     Revised Date:  2013-05-30    
Medline Journal Info:
Nlm Unique ID:  101273479     Medline TA:  Vasc Health Risk Manag     Country:  New Zealand    
Other Details:
Languages:  eng     Pagination:  17-26     Citation Subset:  IM    
Affiliation:
Department of Endocrinology, Mayo Clinic College of Medicine, Scottsdale, AZ, USA. palumbo.pasquale@mayo.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Cardiovascular Diseases / etiology,  mortality,  prevention & control*
Clinical Trials as Topic
Diabetes Mellitus, Type 2 / blood,  complications,  drug therapy*,  mortality
Diabetic Angiopathies / etiology,  mortality,  prevention & control
Drug Therapy, Combination / methods
Hemoglobin A, Glycosylated* / analysis
Humans
Hyperglycemia / complications
Chemical
Reg. No./Substance:
0/Hemoglobin A, Glycosylated
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Role of ICAM-1 and E-selectin gene polymorphisms in pathogenesis of PAOD in Egyptian patients.
Next Document:  Successful management of late right ventricular perforation after pacemaker implantation.